Sugi Predict

Sugi Predict / Compounds / SCHEMBL102449

SCHEMBL102449

SCHEMBL102449

[c]1nc(-c2ccccc2)co1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ NPC1 O15118 3/20 0.38
▸ POLB P06746 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ IDO1 P14902 1/20 0.34
▸ METAP2 P50579 1/20 0.34
▸ KEAP1 Q14145 1/20 0.34
▸ ASIC3 Q9UHC3 1/20 0.34
▸ NOTUM Q6P988 2/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRG2 P18507 1/20 0.33
▸ GABRB3 P28472 1/20 0.33
▸ GABRA5 P31644 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2089433 0.78 NPC1 (0.39) RAB9AKMT2AMEN1NPC1ALDH1A1
SCHEMBL2092720 0.78 ENPP3 (0.46) RAB9AKMT2AMEN1NPC1POLB
SCHEMBL2096790 0.78 NOTUM (0.38) RAB9ANPC1SMN1; SMN2METAP2NOTUM
SCHEMBL9955620 0.77 IDO1 (0.45) RAB9AKMT2AMEN1NPC1ALDH1A1
SCHEMBL9956286 0.77 ENPP3 (0.45) RAB9ANPC1POLBALDH1A1SMN1; SMN2
SCHEMBL9956598 0.77 IDO1 (0.45) RAB9ANPC1SMN1; SMN2IDO1NOTUM
SCHEMBL7387155 0.74 ALDH1A1 (0.35) KMT2AMEN1ALDH1A1ADORA2AADORA1
SCHEMBL2098115 0.74 KIF11 (0.44) RAB9AKMT2AMEN1NPC1POLB
SCHEMBL17028965 0.73 IDO1 (0.49) RAB9AALDH1A1HPGDIDO1NOTUM
SCHEMBL970674 0.72 KDM4E (0.56) RAB9ANPC1POLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 667 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022155419-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. (US) 2022-07-21 — — WO claimed
US-20210292281-A1 PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA REATA PHARMACEUTICALS, INC. (US) 2021-09-23 — — US claimed
EP-3807265-A1 PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA Reata Pharmaceuticals, Inc. (US) 2021-04-21 — — EP claimed
CN-112654610-A Pyrazole and imidazole compounds for inhibiting IL-17 and ROR gamma 里亚塔医药公司 2021-04-13 — — CN claimed
CN-107531690-B 4,5,6, 7-tetrahydro-1H-pyrazolo [4,3-c ] pyridin-3-amine compounds as CBP and/or EP300 inhibitors 基因泰克公司 2020-11-06 — — CN claimed
CN-111423434-A Carbonamide derivative and preparation method thereof 四川海思科制药有限公司 2020-07-17 — — CN claimed
EP-3224258-A1 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS Genentech, Inc. (US) 2017-10-04 — — EP claimed
WO-2016086200-A9 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH, INC. (US) 2016-06-23 — — WO claimed
WO-2016086200-A1 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH, INC. (US) 2016-06-02 — — WO claimed
EP-2461811-B1 MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV IDENIX PHARMACEUTICALS LLC (US) 2016-04-20 — — EP claimed
WO-2003103599-A2 CASPASE-1 INHIBITORS AND METHODS FOR THEIR USE SUNESIS PHARMACEUTICALS, INC. (US) 2003-12-18 — — WO claimed
US-20030186978-A1 Novel telomerase inhibitors PHARMACIA ITALIA, SPA (IT) 2003-10-02 — — US claimed
WO-2003050073-A1 SUBSTITUTED HYDROXYETHYLAMINES ELAN PHARMACEUTICALS, INC. (US) 2003-06-19 — — WO claimed
EP-0863875-B1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY HOFFMANN LA ROCHE (CH) 2003-06-04 — — EP claimed
WO-2002090357-A1 DISUBSTITUTED 1,7-GUANINES PHARMACIA ITALIA S.P.A. (IT) 2002-11-14 — — WO claimed
US-6403633-B2 USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. 2002-06-11 — — US claimed
WO-2001096339-A1 NOVEL TELOMERASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2001-12-20 — — WO claimed
EP-0281012-B1 4-CHLORO-OXAZOLE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1991-12-11 — — EP claimed
US-4892799-A PHOTOCONDUCTIVITY, ELECTROGRAPHY HOECHST AKTIENGESELLSCHAFT (DE) 1990-01-09 — — US claimed
EP-0281012-A1 4-Chloro-oxazole derivatives, method for their preparation and their use HOECHST AKTIENGESELLSCHAFT (DE) 1988-09-07 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292281-A1 PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA RORC, RORB, RORA RAB9A 1311/4885KMT2A 3518/4885MEN1 3080/4885
US-20030186978-A1 Novel telomerase inhibitors TERT, TERF2IP, TERF2 RAB9A 2850/4885KMT2A 1026/4885MEN1 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.